Publications by authors named "Jose Chanona"
Background Cell-free DNA circulates in cancer patients and induces in vivo cell transformation and cancer progression in susceptible cells. Based on this, we hypothesized that depletion of circulating DNA with DNAse I and a protease mix could have antitumor effects. Study design The study aimed to demonstrate that DNAse I and a protease mix can degrade in vitro DNA and proteins from the serum of healthy individuals and cancer patients, and in vivo in serum of Wistar rats,.
View Article and Find Full Text PDFBackground: This study was performed to define prognostic factors and management of minor salivary gland carcinoma of the oral cavity and oropharynx .
Methods: Retrospective analyses of patients with salivary gland carcinoma of the oral cavity or oropharynx, treated in 1989 to 2006. Statistics included univariate analyses to identify prognostic factors associated with disease-free survival (DFS) and disease-specific survival.
Imatinib mesylate inhibits platelet-derived growth factor receptor (PDGFR), and there are evidences that the PDGFR participates in development and progression of cervical cancer. This pilot study was set to evaluate the efficacy in response rate and progression-free survival of imatinib. A secondary end point was to evaluate its safety as second-line treatment of recurrent or metastatic cervical cancer expressing PDGFRalpha.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to investigate how toxic doses of digitalis compounds like ouabain and digoxin induce cell death in guinea pig heart cells (cardiomyocytes).
- The researchers used three groups of guinea pigs, giving two groups toxic doses of digitalis while keeping a control group without it, and then analyzed heart tissue for cell death indicators after five hours.
- The findings showed evidence of apoptosis through DNA fragmentation and cytochrome c release from mitochondria, indicating that digitalis treatment causes significant cell death, although some other death mechanisms may also be involved.
Background: Most cervical cancer patients with pelvic recurrent or persistent disease are not candidates for exenteration, therefore, they only receive palliative chemotherapy. Here we report the results of a novel treatment modality for these patients pre-exenterative chemotherapy- under the rational that the shrinking of the pelvic tumor would allow its resection.
Methods: Patients with recurrent or persistent disease and no evidence of systemic disease, considered not be candidates for pelvic exenteration because of the extent of pelvic tumor, received 3-courses of platinum-based chemotherapy.